N/A N=500 Brevera™ Breast Biopsy System Data Collection Study
Breast Cancer Female
Primary: Procedural Time — 38.44 Minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Positron Emission Mammography (PEM) Biopsy Accessory for the Diagnosis of Breast Cancer
Breast Cancer
Primary: Feasibility That Breast Biopsy Can be Performed Using PEM and Stereo Navigator Software After Diagnostic PEM on the Same Day. — 22; 21; 6; 26 Breast Lesions
Phase 4 N=72 Intra-operative Digital vs. Standard Mammography
Breast Cancer
Primary: Comparison of Operative Time Savings — 48.5; 54; 68; 74 Minutes — p=0.716
N/A N=525 A Post-Market Clinical Trial to Evaluate the Performance and Operation of the Brevera Breast Biopsy System
Breast Cancer Female
Primary: Difference in Procedural Time in Minutes — 42.15; 40.13 procedure time in minutes
N/A N=67 A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy
Breast Cancer
Primary: Number of Participants With Technical Success — 60 Participants
N/A N=298 Diagnostic US for Reduction of Benign Breast Biopsies Using US-guided Optical Tomography
Breast Biopsy
Primary: Impact of US-guided DOT on the Potential Reduction of Benign Biopsies as Measured by Comparing the Reads With a Non- Suspicious Assessment of Conventional Imaging (CI)…
N/A N=39 Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants
N/A N=22 Pilot Study to Evaluate High Resolution PET Image-Guidance for Sampling of Breast Abnormalities
Breast Cancer
Primary: Number of Lesions That Were Successfully Biopsied Using the PET-guided Biopsy Method. — 24 Number of lesions
Phase 4 N=219 Quantitative Subharmonic Breast Imaging
Breast Cancer
Primary: Number of Breast Cancer Lesions Characterized as Malignant or Benign With 3D SHI, Harmonic Imaging (HI) or Power Doppler Imaging (PDI) — 69; 24; 126; 58 lesions
N/A N=2,978 Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
Breast Carcinoma
Primary: Rate of Detection of Invasive Cancers — 9; 14 Participants
N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Phase 2 N=12 Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
Breast Cancer · Ductal Carcinoma in Situ - Category
Primary: 18F-FES Uptake in DCIS — 1.43 SUV
N/A N=60 The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease
Breast Abnormalities
Primary: Specificity of MBI. Specificity is Defined as the Number of True Negatives/ Total Number of Negative Pathology Results. — 27 lesions
N/A N=89 Comparison of MRI and Molecular Breast Imaging in Breast Diagnostic Evaluation
Breast Cancer
Primary: Sensitivity on the Per Patient Level — 25; 27 participants
N/A N=70 Benefit of a Diagnostic MRI in Case of Pathological Nipple Discharge With Normal Mammography / Ultrasound
Breast Cancer
Primary: The Negative Predictive Value (PVV) of MRI
Phase 2 N=100 Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer
Breast Neoplasms
Primary: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan — 100; 100 percentage…
N/A N=245 The Role of Pre-deployment Retraction in Decreasing Biopsy Clip Migration During Stereotactic Breast Biopsies
Breast Biopsy
Primary: Number of Breast Biopsy Patients Whose Clip Migrated Greater Than 10mm From the Biopsy Site. — 46; 44 Participants
N/A N=258 Navigation Endoscopy to Reach Indeterminate Lung Nodules Versus Trans-Thoracic Needle Aspiration
Lung Nodule
Primary: Diagnostic Accuracy — 94; 81 Participants — p=0.003
N/A N=20 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Breast Cancer · Ductal Carcinoma in Situ
Primary: Ipsilateral Recurrence Rate — 0 participants
N/A N=20 Tactile Breast Imaging Sensor for Tumor Malignancy Characterization
Breast Cancer
Primary: Size Error in Millimeters — 0 milimeters
N/A N=193 Pain Monitoring After Breast Biopsy: Benefit of E-health
Breast Cancer · Biopsy Wound
Primary: Number of Participants by Pain Intensity at Day 4 Post Breast Biopsy With a Benefit of Intervention by E-health (Phone Consultation With a Professional or Connected…
N/A N=1,232 Acquisition of Breast Mammography Images
Breast Cancer
Primary: Number of Participants for Whom Study Image Data Were Collected — 642; 124; 244 Participants
N/A N=1,638 Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
Breast Cancer
Primary: Cancer Detection Rate Per 1000 Women Screened, by Breast Density — 3.2; 12.0; 10.7; 0 cancers per 1000 women screened — p=<0.001
N/A N=29 Magnetic Seed Localisation of Breast Cancers
Breast Cancer
Primary: Migration of Sentimark Device — 100 percentage of Magseed migrating >10mm
N/A N=40 Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
Breast Neoplasm
Primary: Negative Predictive Value — 88.2; 85.7; 87.1 percentage of participants
N/A N=25 Breast Cup Immobilization Device II (GCC 1047)
Breast Cancer
Primary: Breast Cup Immobilization Device II (GCC 1047) Feasibility — 25 Participants
N/A N=45 ARFI, VisR and DDAI Ultrasound for Improving Discrimination of Malignant and Unresponsive Breast Cancer
Breast Cancer
Primary: Correlation of Peak Displacement (PD) for Detecting Malignancy — 4.5803; 8.628 microns — p=0.2988
N/A N=72 The Prone to Supine Breast MRI Trial
Breast Cancer
Primary: Number of Successful Segmentation of Supine MRI Images — 54; 61 Participants
Phase 1 N=35 Single Dose Partial Breast Radiotherapy
Breast Cancer
Primary: Maximum Tolerated Dose — 21 Gray (Gy)
Phase 2 N=60 Feasibility Study of Intraoperative Imaging in Breast Cancer
Breast Cancer
Primary: (Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials — 2.1; 4.7; 4.2 Ratio